{
    "0P0000XMRD.L": {
        "short_name": "AXA Framlington Biotech Fund GB",
        "long_name": "AXA Framlington Biotech Fund GBP Z Acc",
        "currency": "GBp",
        "summary": "The aim of this Fund is to provide long-term capital growth. The Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Manager selects shares based upon analysis of a company\u00e2\u0080\u0099s financial status, quality of its management, expected profitability and prospects for growth.",
        "manager_name": "Linden  Thomson",
        "manager_bio": "",
        "category": "Sector Equity Biotechnology",
        "family": "AXA Investment Managers UK Ltd",
        "exchange": "LSE",
        "market": "gb_market",
        "total_assets": null
    },
    "0P0001562A.F": {
        "short_name": "Pluvalca Inno Sant\u00e9 A",
        "long_name": "Pluvalca Health Opportunities A",
        "currency": "EUR",
        "summary": "PLUVALCA HEALTH OPPORTUNITIES a pour objectif de gestion la recherche d\u00e2\u0080\u0099une performance sup\u00c3\u00a9rieure \u00c3\u00a0 10% (nette de frais de gestion) en rythme annuel moyen sur la dur\u00c3\u00a9e de placement recommand\u00c3\u00a9e au travers d\u00e2\u0080\u0099une s\u00c3\u00a9lection rigoureuse de valeurs tout en faisant b\u00c3\u00a9n\u00c3\u00a9ficier ses souscripteurs d\u00e2\u0080\u0099une expertise diff\u00c3\u00a9renciante sur le march\u00c3\u00a9 europ\u00c3\u00a9en en mati\u00c3\u00a8re de s\u00c3\u00a9lection de soci\u00c3\u00a9t\u00c3\u00a9s de biotechnologies innovantes dans le secteur de la sant\u00c3\u00a9.",
        "manager_name": "S\u00c3\u00a9bastien  Lalev\u00c3\u00a9e",
        "manager_bio": "",
        "category": "Sector Equity Biotechnology",
        "family": "Financi\u00c3\u00a8re Arbevel",
        "exchange": "FRA",
        "market": "dr_market",
        "total_assets": 29415000
    },
    "SELJLB.MI": {
        "short_name": "SELECTRA J. LAMARCK BIOTECH CLA",
        "long_name": "Selectra J. Lamarck Biotech Fund Class D",
        "currency": "EUR",
        "summary": "The main objective of this sub-fund is to profit from increasing share prices in the biotechnology sector. The focus is on mature top tier pharmaceutical biotech companies and companies with interesting pipeline of products in development in a single or numerous markets, like Nasdaq or NYSE. The followed investment policy will enable the Sub-Fund to increase overall return relative to the Nasdaq Biotech Index by active stock selection of companies, offering the most promising technology platform.",
        "manager_name": "Not  Disclosed",
        "manager_bio": "",
        "category": "Sector Equity Biotechnology",
        "family": "SELECTRA MANAGEMENT COMPANY S.A.",
        "exchange": "MIL",
        "market": "it_market",
        "total_assets": null
    }
}